Compounds > fenofibric acid
Page last updated: 2024-08-24

fenofibric acid and thiazoles

fenofibric acid has been researched along with thiazoles in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (60.00)18.2507
2000's0 (0.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Auwerx, J; Briggs, M; Deeb, S; Heyman, RA; Lefebvre, AM; Peinado-Onsurbe, J; Schoonjans, K; Staels, B1
Andersson, Y; Fruchart, JC; Kosykh, V; Lefebvre, AM; Majd, Z; Martin, G; Najib, J; Sechkin, AV; Staels, B1
Eriksson, P; Hamsten, A; Nilsson, L; Takemura, T1
Headey, SJ; Rimmer, KA; Velkov, T1
Chew, GT; Sahebkar, A; Watts, GF1

Reviews

1 review(s) available for fenofibric acid and thiazoles

ArticleYear
New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:4

    Topics: Acetates; Animals; Atherosclerosis; Chalcones; Cholesterol, HDL; Dyslipidemias; Fatty Liver; Fenofibrate; Humans; Insulin Resistance; Lipoproteins, HDL; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Propionates; Quinolines; Sulfonamides; Thiazoles; Triazoles; Triglycerides

2014

Other Studies

4 other study(ies) available for fenofibric acid and thiazoles

ArticleYear
PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene.
    The EMBO journal, 1996, Oct-01, Volume: 15, Issue:19

    Topics: 3T3 Cells; Adipocytes; Adipose Tissue; Animals; Cell Line; Dimerization; DNA; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipoprotein Lipase; Liver; Mice; Mice, Inbred C57BL; Myocardium; Organ Specificity; Promoter Regions, Genetic; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation

1996
Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation.
    Arteriosclerosis, thrombosis, and vascular biology, 1999, Volume: 19, Issue:1

    Topics: Aging; Animals; Apolipoprotein C-I; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins C; Fenofibrate; Gene Expression Regulation; Gene Expression Regulation, Developmental; Humans; Hypolipidemic Agents; Kinetics; Liver; Male; Rats; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides

1999
Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells.
    Arteriosclerosis, thrombosis, and vascular biology, 1999, Volume: 19, Issue:6

    Topics: Bezafibrate; Cells, Cultured; Clofibric Acid; Endothelium, Vascular; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Plasminogen Activator Inhibitor 1; Pyrimidines; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription, Genetic

1999
Ligand-enhanced expression and in-cell assay of human peroxisome proliferator-activated receptor alpha ligand binding domain.
    Protein expression and purification, 2010, Volume: 70, Issue:2

    Topics: Butyrates; Fatty Acids, Unsaturated; Fenofibrate; Humans; Ligands; Maltose-Binding Proteins; Mediator Complex Subunit 1; Models, Molecular; Periplasmic Binding Proteins; Phenylurea Compounds; PPAR alpha; Propionates; Protein Binding; Protein Structure, Tertiary; Recombinant Fusion Proteins; Thiazoles

2010